Clinical trial Recruiting at 1 site Early Phase 1 Interventional Ages 18 to 35

Preventing osteoarthritis after ACL injuries with biologic therapy

Official title: Biologic Therapy to Prevent Osteoarthritis After ACL Injury

Run by University of California, Los Angeles · NCT03968913 · Data updated 2026-11-12

This study is testing if a drug called anakinra can help prevent osteoarthritis in young people who have injured their ACL.

Quick facts

PhaseEarly Phase 1
Study typeInterventional
Ages18 Years to 35 Years
SexAll
Enrollment32 (estimated)
SponsorUniversity of California, Los Angeles
Academic / other
Locations1 site (Los Angeles, California)
StatusRecruiting
StartedSeptember 15, 2021
Main results expectedJanuary 30, 2027
Study endsJanuary 30, 2027
Registry record updatedJanuary 26, 2026
Trial IDNCT03968913 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals aged 18 to 35 with a recent MRI-confirmed ACL injury who plan to undergo ACL reconstruction.

Probably not a fit

Patients with previous knee injuries or those who have sustained multi-ligamentous injuries will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of anakinra, an interleukin-1 receptor antagonist, to prevent the development of osteoarthritis in patients who have suffered an anterior cruciate ligament (ACL) injury. The study will enroll 32 participants aged 18 to 35 who will be randomized into two groups: one receiving saline injections as a placebo and the other receiving anakinra injections following knee aspiration. Both groups will undergo two knee aspiration and injection procedures within two weeks of their injury. The goal is to assess whether early intervention with anakinra can reduce the risk of future osteoarthritis.

Why it matters

Potential benefit: If successful, this treatment could significantly reduce the incidence of osteoarthritis in patients recovering from ACL injuries.

How similar studies have gone: Previous studies in animal models have shown promising results with similar approaches, but this specific application in humans is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* patients age 18 to 35 years with closed growth plates as visualized on plain radiographs who participate in cutting and pivoting activities.
* we will enroll an equal number of men and women in each treatment group (16 total per group; 8 men, 8 women).
* study participants must have an MRI-confirmed ACL injury within 2 weeks of presentation
* must elect to undergo bone-patellar tendon-bone (BTB) autograft ACL reconstruction within 45 days of injury
* no clinical or MRI evidence of posterior cruciate ligament injury
* no more than grade 1 medial collateral ligament injury
* no concurrent posterolateral corner injury to the ipsilateral knee

Exclusion Criteria:

* injury occurring more than 2 weeks prior to enrollment
* previous ipsilateral knee injury
* multi-ligamentous knee injury
* pre-existing or concurrent grade 3 or 4 chondral (cartilage) injuries
* previous ipsilateral knee surgery (meniscus tear, ACL tear, chondral injury, etc.)
* of note, concurrent acute meniscus injury is NOT an exclusion criteria
* active infection
* known allergy or adverse reaction to anakinra
* intra-articular cortisone injection into either knee within 3 months of injury
* prior exposure to IL-1Ra
* participation in another clinical drug trial within the 4 weeks before injury
* history of any coagulopathy or current anti-coagulation therapy
* current malignancy
* current inflammatory/rheumatologic disease
* current immune-compromised state
* current renal failure

Where it's running

  • University of California, Los Angeles
    Los Angeles, California, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.